ANDREONE, Pietro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.785
AS - Asia 16.028
EU - Europa 8.594
SA - Sud America 2.406
AF - Africa 414
OC - Oceania 49
Continente sconosciuto - Info sul continente non disponibili 17
Totale 54.293
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.335
SG - Singapore 4.963
CN - Cina 3.298
HK - Hong Kong 2.991
VN - Vietnam 2.021
GB - Regno Unito 1.828
BR - Brasile 1.827
FI - Finlandia 1.136
IT - Italia 1.104
SE - Svezia 1.061
RU - Federazione Russa 706
KR - Corea 685
DE - Germania 623
FR - Francia 378
BG - Bulgaria 371
IN - India 358
PL - Polonia 355
BD - Bangladesh 253
AR - Argentina 235
TR - Turchia 235
ID - Indonesia 227
CA - Canada 199
UA - Ucraina 170
NL - Olanda 164
JP - Giappone 153
MX - Messico 151
ZA - Sudafrica 148
IQ - Iraq 144
AE - Emirati Arabi Uniti 122
ES - Italia 115
AT - Austria 108
LT - Lituania 75
EC - Ecuador 74
IE - Irlanda 74
PK - Pakistan 74
CO - Colombia 71
EG - Egitto 60
CL - Cile 54
MA - Marocco 54
SA - Arabia Saudita 54
UZ - Uzbekistan 51
CZ - Repubblica Ceca 50
PH - Filippine 46
VE - Venezuela 45
BE - Belgio 39
MY - Malesia 39
JO - Giordania 37
DZ - Algeria 36
PY - Paraguay 35
RO - Romania 35
AU - Australia 33
TN - Tunisia 31
KZ - Kazakistan 28
IL - Israele 26
PE - Perù 26
KE - Kenya 24
AZ - Azerbaigian 23
NP - Nepal 23
TH - Thailandia 22
ET - Etiopia 21
AL - Albania 20
CR - Costa Rica 20
UY - Uruguay 20
CH - Svizzera 19
IR - Iran 19
GR - Grecia 18
BO - Bolivia 17
DO - Repubblica Dominicana 16
NO - Norvegia 16
KG - Kirghizistan 15
A2 - ???statistics.table.value.countryCode.A2??? 14
PT - Portogallo 14
NZ - Nuova Zelanda 13
OM - Oman 13
RS - Serbia 13
TW - Taiwan 13
LB - Libano 12
MK - Macedonia 12
BH - Bahrain 11
DK - Danimarca 11
GE - Georgia 11
LV - Lettonia 10
MD - Moldavia 10
PR - Porto Rico 10
QA - Qatar 10
EE - Estonia 9
HN - Honduras 9
HU - Ungheria 9
BY - Bielorussia 8
CY - Cipro 7
JM - Giamaica 7
KH - Cambogia 7
SK - Slovacchia (Repubblica Slovacca) 7
BA - Bosnia-Erzegovina 6
LA - Repubblica Popolare Democratica del Laos 6
PA - Panama 6
PS - Palestinian Territory 6
SI - Slovenia 6
SY - Repubblica araba siriana 6
GT - Guatemala 5
Totale 54.185
Salva come PNG Salva come JPEG
Città #
Santa Clara 3.472
Singapore 3.213
Ashburn 2.998
Hong Kong 2.943
Fairfield 2.373
Chandler 2.080
Helsinki 1.087
London 987
Nyköping 857
New York 854
Woodbridge 848
Houston 780
Wilmington 753
Hefei 706
Seattle 698
San Jose 655
Ho Chi Minh City 639
Cambridge 625
Beijing 594
Seoul 572
The Dalles 563
Los Angeles 551
Hanoi 504
Chicago 480
Ann Arbor 475
San Diego 468
Princeton 372
Council Bluffs 362
Sofia 359
Southend 344
Warsaw 335
Moscow 221
Orem 204
Shanghai 194
Buffalo 188
Salt Lake City 186
Modena 182
Jersey City 175
São Paulo 173
Jakarta 155
Dearborn 152
Jacksonville 148
Dallas 118
Redondo Beach 113
Tokyo 113
Da Nang 110
Istanbul 104
Milan 101
Porto Alegre 97
Frankfurt am Main 90
Lauterbourg 90
Chennai 88
Haiphong 87
Bremen 86
Johannesburg 86
Bupyeong-gu 82
Denver 72
Tampa 71
Dublin 68
Vienna 68
Munich 66
Phoenix 65
Elk Grove Village 64
Rome 64
Atlanta 62
Bologna 60
Amsterdam 59
Brooklyn 58
Norwalk 56
Rio de Janeiro 55
Montreal 53
Nuremberg 52
Stockholm 52
Mexico City 51
Viroflay 51
Manchester 50
Paris 49
Toronto 49
Guangzhou 48
Izmir 48
San Francisco 46
Biên Hòa 45
Baghdad 44
Kent 44
Kilburn 44
Tashkent 44
Augusta 43
Mumbai 43
Des Moines 42
Dhaka 41
Grafing 41
Sterling 41
Poplar 39
Boston 38
Curitiba 36
San Mateo 36
Brussels 35
Detroit 35
Brno 34
Belo Horizonte 33
Totale 38.085
Salva come PNG Salva come JPEG
Nome #
Non-alcoholic steatohepatitis and liver transplantation 518
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 381
Nonalcoholic steatohepatitis before and after liver transplant: keeping up with the times 376
Adefovir and lamivudine combination therapy is superior to ADV monotherapy for lamivudine-resistant patients with HBeAG-negative chronic hepatitis B 346
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 330
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 322
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 319
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 311
Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes 310
A new prognostic model to predict dropout from the waiting list in cirrhotic candidates for liver transplantation with MELD score <18. 300
Combined blockade of programmed death-1 and activation of CD137 increase responses of human liver T cells against HBV, but not HCV 299
De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients 296
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 296
Missed treatment in an Italian HBV infected patients cohort: HBV RER 286
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 278
From current status to optimization of HCV treatment: Recommendations from an expert panel 272
The time has come to look for metabolic dysfunction-associated fatty liver disease in adult patients with type 1 Gaucher disease 269
Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals 264
Pre-transplant diabetes predicts atherosclerotic vascular events and cardiovascular mortality in liver transplant recipients: a long-term follow-up study 262
Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials 258
Treatment of nonalcoholic steatohepatitis in adults: present and future 255
Association of nonalcoholic fatty liver disease (Nafld) with peripheral diabetic polyneuropathy: A systematic review and meta-analysis 252
Molecular and functional characterization of CD133+ stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells 250
X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis 245
Global multi-stakeholder endorsement of the MAFLD definition 244
Liver steatosis is highly prevalent and is associated with metabolic risk factors and liver fibrosis in adult patients with type 1 Gaucher disease 240
Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results 237
Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: Preliminary results of the “A.I.S.F.-EPASCO” Study. 233
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 232
Predictors of solid extra-hepatic non-skin cancer in liver transplant recipients and analysis of survival: a long-term follow-up study 232
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 231
Adaptive response in Hepatitis B virus infection 230
Genetic characterization of adult-onset cryptogenic cholestasis: a prospective multicentre study of 233 patients 225
Menopause, and not age, is a critical factor associated with a worse response to antiviral therapy in women affected by chronic hepatitis C 225
Study of the Serum Metabolomic Profile in Nonalcoholic Fatty Liver Disease: Research and Clinical Perspectives 224
Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing 222
What to start with in first line treatment of chronic hepatitis B patients: an Italian multicentre observational cohort, HBV-RER study group 217
Characteristics of hepatocellular carcinoma in Italy 215
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 215
Liver Stiffness measurments using Fibroscan after three months of IFN-based antiviral therapy is unlikely to predict viral response in cirrhotic patients 213
Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report 213
Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data. 211
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study 208
Update on Alcohol and Viral Hepatitis 206
Adherence to Mediterranean diet in liver transplant recipients: a cross-sectional multicenter study 205
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma 205
Quality of life of hepatitis B virus surface antigen-positive patients with suppressed viral replication: comparison between inactive carriers and nucleot(s)ide analog-treated patients 203
Development of different psychiatric manifestations during antiviral therapy for chronic hepatitis C. 202
5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial 198
The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives 198
Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C 197
A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices 197
CD 133+ stem cells for the treatment of end stage liver disease 197
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 196
Grazoprevir/elbasvir fixed-dose combination for hepatitis C 195
Demographic, etiological and clinical features of liver cirrhosis at the onset of the first episode of clinical decompensation: Preliminary results of the “A.I.S.F.-EPASCO” 194
Clinical and serological profile of primary biliary cirrhosis in men 194
Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study 194
Gross pathologic types of hepatocellular carcinoma in Italy. 193
A New Two-Dimensional Shear Wave Elastography for Noninvasive Assessment of Liver Fibrosis in Healthy Subjects and in Patients with Chronic Liver Disease - Eine neue zweidimensionale Shear-Wave-Elastografie zur nicht-invasiven Beurteilung der Leberfibrose bei Gesunden und bei Patienten mit chronischer Lebererkrankung 193
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 192
A new approach to the use of α-fetoprotein as surveillance test for hepatocellular carcinoma in patients with cirrhosis 192
ABT-450: A novel agent for the treatment of CHC genotype 1: Focus on treatment-experienced patients 192
Working together to tackle HCV infection: Ombitasvir/paritaprevir/ritonavir and dasabuvir combination 191
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of non-responder patients with chronic hepatitic C 191
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir 190
Alcohol and viral hepatitis: a mini-review 190
Transjugular intrahepatic portosystemic shunt does not affect the efficacy and safety of direct-acting antivirals in patients with advanced cirrhosis: a real-life, case-control study 188
Safety and efficacy of once daily ledipasvir/sofosbuvir fixed-dose combination in patients with chronic hepatitis C 188
Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study 184
Chronic hepatitis B: Are we close to a cure? 184
Combined GS-4774 and Tenofovir Therapy Can Improve HBV-Specific T-Cell Responses in Patients With Chronic Hepatitis 183
Acquired intestinal lymphangiectasia successfully treated with a low fat and MCT-enriched diet in a patient with liver transplantation 182
Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C 180
Familial intrahepatic cholestasis: New and wide perspectives 179
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation 179
Assessment of Liver Fibrosis With Elastography Point Quantification vs Other Noninvasive Methods 176
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 176
Prevalence of and risk factors for fatty liver in the general population of Northern Italy: The Bagnacavallo Study 175
An in-depth psychosocial and biochemical evaluation in transplant recipients for alcoholic liver disease should be planned 175
A Placebo-controlled trial of obeticholic acid in primary biliary cholangitis 174
Risk factors in acute diabetic foot syndrome: analysis of 75 consecutive patients referred to a tertiary center in Modena, Italy 172
Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants 172
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis 172
Calcineurin inhibitors levels reduction during treatment with Sofosbuvir in liver transplanted patients 171
Allocation priority in non urgent liver transplantation: an overview of proposed scoring systems 171
Quality of life in liver transplant recipients during the Corona virus disease 19 pandemic: A multicentre study 171
Anti-HBs re-seroconversion after liver transplantation in a patient with past HBV infection receiving a HBsAg positive graft 170
Comparing and combining gamma-hydroxybutiric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomized comparative study 170
Atopic dermatitis associated with autoimmune, cardiovascular and mental health comorbidities: a systematic review and meta-analysis 170
Indomethacin increases 2′,5′-oligoadenylate synthetase release by cultured liver tissue of patients with HCV chronic active hepatitis 169
La fibrosi epatica: aggiornamenti su fisiopatologia, diagnosi e prognosi 169
Metronomic capecitabine in advanced hepatocellular carcinoma patients:a phase II study 169
G-CSF administration is not related to Peg-IFN alfa-2b treatment duration nor response in liver transplanted patients with HCV recurrence 168
Long-term antiviral treatment for recurrent hepatitis C after liver transplantation 168
Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis 168
Antibodies against pegylated interferon-alpha affect response to treatment in patients with chronic hepatitis C 167
Virological Treatment Monitoring for Chronic Hepatitis B 166
Clinical Impact and behaviour of serum autoantibodies in adult liver transplantation 166
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis 166
Totale 22.005
Salva come PNG Salva come JPEG
Categoria #
all - tutte 283.390
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 283.390
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.232 0 0 0 0 0 0 0 0 0 142 954 136
2021/20225.712 823 485 224 244 116 343 259 413 702 635 802 666
2022/20235.217 696 568 387 500 607 793 72 540 688 31 204 131
2023/20243.483 133 234 153 334 874 178 194 505 99 72 161 546
2024/202512.345 463 84 65 962 2.405 1.716 518 929 1.506 944 1.111 1.642
2025/202622.209 1.254 771 1.937 2.630 3.300 2.823 3.041 1.658 2.592 2.203 0 0
Totale 54.815